Close Menu
  • Home
  • Stock
  • Parenting
  • Personal
  • Fashion & Beauty
  • Finance & Business
  • Marketing
  • Health & Fitness
  • Tech & Gadgets
  • Travel & Adventure

Subscribe to Updates

Subscribe to our newsletter and never miss our latest news

Subscribe my Newsletter for New Posts & tips Let's stay updated!

What's Hot

Perplexity’s Comet and The Browser Company’s Dia Browser Unveil New Feature to Automate Repetitive Tasks

julio 22, 2025

Earth to Spin Faster on July 22 to Make It One of the Shortest Days in Recorded History

julio 22, 2025

Acer Predator Helios Neo 16 AI Launched in India Alongside 16S AI Laptop: Price, Specifications

julio 22, 2025
Facebook X (Twitter) Instagram
  • Home
  • Contact us
  • DMCA
  • Política de Privacidad
  • Publicidad en DD Noticias
  • Sobre Nosotros
  • Términos y Condiciones
Facebook X (Twitter) Instagram
DD Noticias: Tu fuente de inspiración diariaDD Noticias: Tu fuente de inspiración diaria
  • Home
  • Stock
  • Parenting
  • Personal
  • Fashion & Beauty
  • Finance & Business
  • Marketing
  • Health & Fitness
  • Tech & Gadgets
  • Travel & Adventure
DD Noticias: Tu fuente de inspiración diariaDD Noticias: Tu fuente de inspiración diaria
Home » Wall Street’s top analyst calls
Stock

Wall Street’s top analyst calls

Jane AustenBy Jane Austenfebrero 10, 2025No hay comentarios4 Mins Read
Facebook Twitter Pinterest LinkedIn Tumblr Email
Share
Facebook Twitter LinkedIn Pinterest Email


Amazon downgraded, Shopify upgraded: Wall Street's top analyst calls
Amazon downgraded, Shopify upgraded: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here are today’s research calls that investors need to know, as compiled by The Fly.

Top 5 Upgrades:

Benchmark upgraded Shopify (SHOP) to Buy from Hold with a $150 price target. The firm expects «comfortable upside» to reported and guided gross merchandise value, but with more enterprise and Plus-driven upside to monthly recurring revenue and GMV than witnessed historically.

Loop Capital upgraded Aspen Technology (AZPN) to Buy from Hold with a price target of $315, up from $265. The firm believes that Elliott’s attempt to leverage its 9% stake in Aspen and oppose the current tender offer from Emerson will likely result in a meaningfully higher bid.

BofA upgraded Mobileye (MBLY) to Neutral from Underperform with a price target of $19, up from $12. 2025 guidance provided along with the Q4 report was below BofA and consensus, but it limits downside risk to estimates, the firm tells investors.

UBS upgraded Johnson Controls (JCI) to Buy from Neutral with a price target of $103, up from $90, implying about 20% upside from current levels. The firm is positive on the appointment of the new, outsider CEO Joakim Weidemanis, and has now greater confidence in Johnson’s profit improvement potential.

Wolfe Research upgraded Oneok (OKE) to Outperform from Peer Perform with a $110 price target. The company’s export joint venture with MPLX creates strategic value and adds to a proposition of competitive growth coupled with rapidly increasing capital return, the firm tells investors in a research note.

Top 5 Downgrades:

Phillip Securities downgraded Amazon.com (AMZN) to Accumulate from Buy with a price target of $270, up from $240, post the Q4 report. The firm cites valuation for the downgrade following the recent strength in the shares.

Argus downgraded Skyworks (SWKS) to Hold from Buy. The firm notes Apple (AAPL) is by far Skyworks’s largest customer, but it will now dual-source a premier RF socket in the new upcoming iPhone 17 generation family that Skyworks had formerly sole-sourced, and further points out the company has recently revealed that it would lose 20%-25% content in the iPhone 17 launch due to launch in fall 2025.

Susquehanna downgraded NetApp (NTAP) to Neutral from Positive with a price target of $130, down from $155. The firm sees increased downside risk to consensus estimates, especially in the July and October quarters, as NetApp’s compares become challenging.

Barclays downgraded Illumina (ILMN) to Underweight from Equal Weight with a price target of $100, down from $130. The firm sees greater risk to management’s ability to deliver on their plan due to China uncertainty and increasing competition from Roche in the clinical market.

TD Cowen downgraded Merck (MRK) to Hold from Buy with a price target of $100, down from $121. The firm says its Buy thesis «broke down» with Gardasil’s challenges in China.

Story Continues

Top 5 Initiations:

BofA reinstated coverage of Capri Holdings (CPRI) with a Neutral rating and $23 price target. The health of Capri’s brands has deteriorated, though the potential for these brands to recover from trough sales and margins «provides a counterpoint that balances our relatively bleak view of the near-term fundamentals,» says the firm, which points out that sales and earnings have declined for the past nine quarters and that management sees FY26 being «another challenged year.»

BMO Capital initiated coverage of Flowco (FLOC) with an Outperform rating and $33 price target. The firm likes the company’s «differentiated» technology and market leadership in artificial lift and methane abatement businesses. Piper Sandler, Jefferies, and JPMorgan also started coverage of the stock with Buy-equivalent ratings.

TD Cowen initiated coverage of Repligen (RGEN) with a Buy rating and $200 price target. Repligen is well positioned for «industry-leading» growth and margin expansion as it is over-indexed exposure to new modalities and differentiated product offerings, the firm tells investors in a research note.

Laidlaw initiated coverage of Lifeward (LFWD) with a Buy rating and $10 price target. The firm says ReWalk «is likely to be on the cusp of a rapid revenue ramp up» period beginning from 2025, while the shares are «highly undervalued» at the current price.

Oppenheimer initiated coverage of ARS Pharmaceuticals (SPRY) with an Outperform rating and $40 price target. As the first and only approved needle-free epinephrine product, neffy has the potential to transform the treatment paradigm for patients with severe allergic reactions, including anaphylaxis away from daunting epinephrine autoinjector devices and toward a user-friendly intranasal spray with comparable efficacy, the firm notes.



Source link

Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
Jane Austen
  • Website

Related Posts

Fast fashion pioneer Forever 21 files for bankruptcy — again

marzo 18, 2025

Dow gains 350 points as stocks climb for 2nd day after S&P 500 enters correction

marzo 18, 2025

Yellow Creditors Have Own Plan to Share Trucker’s $550 Million

marzo 18, 2025
Add A Comment
Leave A Reply Cancel Reply

Editors Picks

Fast fashion pioneer Forever 21 files for bankruptcy — again

marzo 18, 2025

Dow gains 350 points as stocks climb for 2nd day after S&P 500 enters correction

marzo 18, 2025

Yellow Creditors Have Own Plan to Share Trucker’s $550 Million

marzo 18, 2025

Alphabet in Talks to Buy Startup Wiz for $30 Billion, WSJ Says

marzo 18, 2025
Top Reviews
DD Noticias: Tu fuente de inspiración diaria
Facebook X (Twitter) Instagram Pinterest Vimeo YouTube
  • Home
  • Contact us
  • DMCA
  • Política de Privacidad
  • Publicidad en DD Noticias
  • Sobre Nosotros
  • Términos y Condiciones
© 2025 ddnoticias. Designed by ddnoticias.

Type above and press Enter to search. Press Esc to cancel.